The stock of Eagle Pharmaceuticals Inc (NASDAQ:EGRX) is a huge mover today! About 285,519 shares traded hands. Eagle Pharmaceuticals Inc (NASDAQ:EGRX) has risen 122.71% since April 14, 2016 and is uptrending. It has outperformed by 118.02% the S&P500.
The move comes after 7 months negative chart setup for the $1.17 billion company. It was reported on Nov, 16 by Barchart.com. We have $69.71 PT which if reached, will make NASDAQ:EGRX worth $105.30M less.
Eagle Pharmaceuticals Inc (NASDAQ:EGRX) Ratings Coverage
Out of 4 analysts covering Eagle Pharma (NASDAQ:EGRX), 4 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. Eagle Pharma has been the topic of 9 analyst reports since July 29, 2015 according to StockzIntelligence Inc. The firm earned “Overweight” rating on Wednesday, July 29 by Piper Jaffray. RBC Capital Markets maintained the stock with “Outperform” rating in Tuesday, May 10 report. The rating was maintained by Mizuho on Wednesday, October 26 with “Buy”. The firm earned “Buy” rating on Wednesday, December 9 by Mizuho. Mizuho downgraded the stock to “Neutral” rating in Monday, June 20 report. The company was maintained on Wednesday, November 2 by William Blair. The stock has “Buy” rating given by Mizuho on Friday, February 26. Mizuho upgraded Eagle Pharmaceuticals Inc (NASDAQ:EGRX) on Thursday, November 3 to “Buy” rating. RBC Capital Markets maintained the stock with “Outperform” rating in Thursday, November 3 report.
According to Zacks Investment Research, “Eagle Pharmaceuticals, Inc. is a specialty pharmaceutical company. It focuses on developing and commercializing injectable products primarily in the critical care and oncology areas in the United States. The Company markets EP-1101 to treat heparin-induced thrombocytopenia. It develops EP-3101, EP-3102, Ryanodex and EP-4104. Eagle Pharmaceuticals, Inc. is based in Woodcliff Lake, New Jersey.”
More recent Eagle Pharmaceuticals Inc (NASDAQ:EGRX) news were published by: Fool.com which released: “Why Eagle Pharmaceuticals, Inc. Is Soaring 21.6% Today” on November 02, 2016. Also Businesswire.com published the news titled: “Eagle Pharmaceuticals, Inc. Reports Third Quarter 2016 Results” on November 09, 2016. Businesswire.com‘s news article titled: “Eagle Pharmaceuticals Signs Definitive Agreement to Acquire Arsia Therapeutics …” with publication date: November 11, 2016 was also an interesting one.
EGRX Company Profile
Eagle Pharmaceuticals, Inc., incorporated on January 2, 2007, is a specialty pharmaceutical company. The Firm focuses on developing and commercializing injectable products in the critical care and oncology areas. The Company’s product portfolio includes EP-1101 (argatroban); Ryanodex (dantrolene sodium); docetaxel injection, non-alcohol formulation (Non-Alcohol Docetaxel Injection); diclofenac-misoprostol; EP-3101 (Bendamustine Hydrochloride Injection, ready-to-dilute (RTD) concentrate solution), and EP-3102 (rapidly infused bendamustine RTD) (EP-3102 Bendeka). The Firm has over four product candidates in advanced stages of development, and/or under review for approval by the United States Food and Drug Administration (FDA), which include EP-6101 Kangio ready-to-use (RTU) bivalirudin; EP-4104 (dantrolene sodium) (EP-4104) for exertional heat stroke (EHS), and EP-5101 (pemetrexed) (EP-5101). The Company’s near-term product candidate, Kangio is a liquid intravenous form of Angiomax for percutaneous transluminal angioplasty.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.